Involving Antibody Fragments Patents (Class 436/512)
-
Patent number: 5856201Abstract: A cellulose binding domain (CBD) having a high affinity for crystalline cellulose and chitin is disclosed, along with methods for the molecular cloning and recombinant production thereof. Fusion products comprising the CBD and a second protein are likewise described. A wide range of applications are contemplated for both the CBD and the fusion products, including drug delivery, affinity separations, and diagnostic techniques.Type: GrantFiled: October 27, 1994Date of Patent: January 5, 1999Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, The University of CaliforniaInventors: Oded Shoseyov, Itai Shpiegl, Marc A. Goldstein, Roy H. Doi
-
Patent number: 5840587Abstract: The invention provides phospholipid coated particles capable of specifically binding antiphospholipid antibodies and a method for preparing such particles. Methods are also provided for determining antiphospholipid antibodies in a serum or plasma. Also provided are methods for isolating antiphospholipid antibodies from a fluid and for raising specific antiphospholipid antibodies.Type: GrantFiled: June 7, 1995Date of Patent: November 24, 1998Assignee: University Hospitals BoardInventors: Michael W. Stewart, Phillip A. Gordon, Wai Sum Etches
-
Patent number: 5837550Abstract: The invention relates to a method by which expression cDNA clone banks are screened by means of IgE antibodies derived from the sera of allergic individuals, or by means of monoclonal or polyclonal antibodies. This type of screening is used for the detection of polynucleotides whose open-reading frames code for allergenically active proteins. These proteins are characterized in that their biological activity as allergens is equal to that of plant allergens occurring in nature.Type: GrantFiled: June 7, 1994Date of Patent: November 17, 1998Assignee: Biomay Produktions-Und Handelsgesellschaft m.b.H.Inventors: Michael Breitenbach, Dietrich Kraft, Helmut Rumpold, Otto Scheiner, Heimo Breiteneder, Karin Pettenburger, Rudolf Valenta
-
Patent number: 5834212Abstract: Anti-human stromelysin monoclonal antibodies reactive with latent and active forms of stromelysin without discrimination between the two, each being immunoreactive with only one of the antigenic determinants of human stromelysin, are provided. The use of a combination of two such monoclonal antibodies which specifically react with different antigenic determinants of human stromelysin renders it possible to accurately determine the amount of human stromelysin in human body fluids, and thus to carry out the diagnosis of rheumatoid arthritis.There are thus provided said monoclonal antibodies per se, a sandwich enzyme immunoassay for the determination of the amount of human stromelysin in human body fluid samples using a combination of two such monoclonal antibodies, and a method for the diagnosis of rheumatoid arthritis using said immunoassay.Type: GrantFiled: April 6, 1995Date of Patent: November 10, 1998Inventors: Yasunori Okada, Masayoshi Shinmei, Taro Hayakawa, Kazushi Iwata, Yumi Korin, Shuji Kodama, Shinichi Yoshida
-
Patent number: 5817458Abstract: Fluorometric immunological assay method for detection of HIV-1 infection in which Murine anti-gp120 monoclonal antibodies coupled to paramagnetic microspheres (14) and Fluorescein conjugated anti-gp120 polyclonal antibodies IgG (16) are incubated in a few drops of whole blood diluted in 0.5 cc phosphate buffered saline (10). After incubation for 5 minutes, the HIV-infected peripheral blood lymphocytes (18) will be coated with both the Murine anti-gp120 monoclonal antibodies coupled to paramagnetic microspheres (14) and Fluorescein conjugated anti-gp120 polyclonal antibodies IgG (16) at exposed gp120 antigens (20) binding sites. At the time of measurement said HIV- infected peripheral blood lymphocytes (18) will be pulled against the wall of the measurement vessel by means of a magnetic gradient (26). The cells adhering to the vessel wall are illuminated at 488 nm monochromatic light by a focused light source (28) and the resultant emitted fluorescence is imaged, measured and recorded.Type: GrantFiled: October 15, 1996Date of Patent: October 6, 1998Assignee: The Avriel Group, AMCAS Division Inc.Inventors: Chester F. King, Robert A. Hallowitz
-
Patent number: 5804391Abstract: The invention concerns the use of a composition which is composed of several different antibodies or/and antibody fragments which serves as a reagent to eliminate rheumatoid factor interference in an immunochemical method.Type: GrantFiled: April 11, 1997Date of Patent: September 8, 1998Assignee: Boehringer Mannheim GmbHInventors: Volker Klemt, Dittmar Schlieper, Urban Schmitt, Michael Wiedmann
-
Patent number: 5798212Abstract: The invention provides a method of assessment of carbohydrate-deficient transferrin in a transferrin containing body fluid, said method comprising the steps of:i) obtaining a transferrin containing liquid sample of or derived from a said fluid;ii) contacting said sample with a source of iron ions;iii) subsequently contacting said sample with an anionic ion exchange resin at a pH such as to cause carbohydrate-deficient transferrin to be retained by said resin;iv) subsequently contacting said resin with an eluant serving to release carbohydrate-deficient transferrin into the eluate from said resin;v) collecting a volume of said eluate substantially free from tetra- and penta-sialo transferrin; andvi) assessing the transferrin variant content in said volume of eluate.By including at least a proportion of the trisialotransferrin in the eluate, it is possible to use relatively simple assessment techniques such as turbidimetry in the assay.Type: GrantFiled: September 9, 1996Date of Patent: August 25, 1998Assignee: Axis Biochemicals ASAInventor: Erling Sundrehagen
-
Patent number: 5798273Abstract: The present invention relates to a method and assay device for detecting small analytes. The results of the assay can be directly read from the device, which is a lateral flow device.Type: GrantFiled: September 25, 1996Date of Patent: August 25, 1998Assignees: Becton Dickinson and Company, Millipore CorporationInventors: John K. Shuler, Stephen J. Lovell, Abigail S. Fisher, Alan J. Weiss, Robert W. Rosenstein
-
Patent number: 5798448Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.Type: GrantFiled: May 15, 1995Date of Patent: August 25, 1998Assignee: Genentech, Inc.Inventors: Ingrid W. Caras, John W. Winslow
-
Patent number: 5776697Abstract: A process for detection of blood cells in activated form and/or determination of a proportion of activated blood cells which comprises performing said detection and/or determination with bird antibodies, whereby interfering interactions which change expression of antigen on a surface of blood cells are eliminated.Type: GrantFiled: February 7, 1994Date of Patent: July 7, 1998Inventors: Tomas Lindahl, Anders Larsson
-
Patent number: 5766960Abstract: A membrane comprising a closely packed array of self-assembling amphiphilic molecules, and is characterized in that it incorporates a plurality of ion channels, and/or at least a proportion of the self-assembling molecules comprise a receptor molecule conjugated with a supporting entity. The ion channel is selected from the group consisting of peptides capable of forming helices and aggregates thereof, corronands, cryptands, podands and combinations thereof. In the amphiphilic molecules comprising a receptor molecule conjugated with a supporting entity, the receptor molecule has a receptor site and is selected from the group consisting of immunoglobulins, antibodies, antibody fragments, dyes enzymes and lectins. "The supporting entity is selected from the group consisting of a lipid head group, a hydrocarbon chain(s), a cross-linkable molecule and a membrane protein. The supporting entity is attached to the receptor molecule at tan end remote from the receptor site.Type: GrantFiled: May 23, 1995Date of Patent: June 16, 1998Assignee: Australian Membrane and Biotechnology Research InstituteInventors: Bruce Andrew Cornell, Vijoleta Lucija Bronislava Braach-Maksvytis
-
Patent number: 5747526Abstract: Herein described is an invention of the usage, design and effective procedures 1.) for selected combined methods for preparation and 2.) for coordination of sequence, dosage and administration in utilizing anti-HIV thiophenoyl urea TUR (or related drugs) chemotherapy as well as for utilizing HIV induced or augmented nonvirion antigen NVA (or early polypeptide vaccine EPV or related or derivative) immunotherapy in treatment of HIV+ and AIDS patients (and applicable to Karposi's sarcoma and to other retroviral diseases). Herein described is an invention of 3.Type: GrantFiled: January 25, 1996Date of Patent: May 5, 1998Inventor: Ariel C. Hollinshead
-
Patent number: 5741712Abstract: The present invention provides a biosensor that detects an analyte in a sample by measuring the response of a membrane within which associated ion channels undergo state changes upon interaction between the analyte and the ionic channels. The state change response is detected as result of the change in ionic flow through the membrane.Type: GrantFiled: May 23, 1995Date of Patent: April 21, 1998Assignee: Australian Membrane and Biotechnology Research InstituteInventors: Bruce Andrew Cornell, Vijoleta Lucija Bronislava Braach-Maksvytis
-
Patent number: 5736344Abstract: A method of assaying bone collagen breakdown levels in a human subject useful to screen for the presence of bone resorption disorders. Also disclosed is a method for monitoring the progression and/or treatment response of a cancer condition which involves or has the potential to progress to a metastatic condition which involves abnormalities in bone resorption rates.Type: GrantFiled: June 7, 1995Date of Patent: April 7, 1998Assignee: Metra Biosystems, Inc.Inventors: Viola T. Kung, Baltazar Gomez, Jr.
-
Patent number: 5719032Abstract: Methods and compositions are provided for detecting antigens having a specific epitope associated with melanoma and prostatic carcinoma. The epitope is present in melanoma cells and prostatic cancer cells but is essentially absent from melanocytes and normal prostatic tissue. The antibody can be used in diagnostic methods for histochemical detection of human melanoma and prostate carcinoma, of various progression stages and in treatment of melanoma and prostate carcinoma.Type: GrantFiled: May 28, 1996Date of Patent: February 17, 1998Assignee: University of British ColumbiaInventor: Juergen R. Vielkind
-
Patent number: 5716790Abstract: Seed lysine is detected by an immunoassay in which anti-EF antibody binds seed protein. Seed EF concentration is highly correlated with seed lysine content.Type: GrantFiled: January 30, 1996Date of Patent: February 10, 1998Assignee: Arizona Board of RegentsInventors: Gloverson L. Moro, Jeffrey E. Habben, Brian A. Larkins
-
Patent number: 5710009Abstract: Assays using receptor:reland complexes capable of releasing the reland in the presence of an analyte are described, wherein the reland does not detectably compete with analyte for binding to the receptor. The dissociation constant of the reland and the receptor is such that no appreciable release of reland occurs in the absence of analyte for the receptor. In a preferred embodiment, the association constant of the monomeric reland and the receptor is less than or equal to about 10.sup.5 M, preferably 10.sup.3 to 10.sup.5 M, most preferably 1% or less of the association constant of the analyte and receptor. In a preferred embodiment, the reland is labelled and the amount of analyte bound to the receptor is determined from the amount of labelled reland which is released.Type: GrantFiled: June 22, 1995Date of Patent: January 20, 1998Assignee: Serex, Inc.Inventors: Judith Fitzpatrick, Regina Lenda
-
Patent number: 5710005Abstract: Methods for determining the concentration of an analyte in a sample in which an analyte gradient is established and brought into contact with one or more zones that contain binding members that interact with the analyte and thereby produce a detectable signal. Devices that may be used to practice the disclosed methods are also provided.Type: GrantFiled: October 29, 1996Date of Patent: January 20, 1998Assignee: Biocode, Inc.Inventor: James H. Rittenburg
-
Patent number: 5693477Abstract: The present invention provides a method of detecting an analyte in a sample the method comprising adding a sample suspected of containing the analyte to a membrane comprising a closely packed array of self-assembling amphiphilic molecules, the membrane including a plurality of ion channels selected from the group consisting of peptides capable of forming helices and aggregates thereof, podands cryptands and coronands, a first receptor moiety reactive with the analyte being attached to the ion channel at an end thereof, the first receptor moiety being such that it normally exists in a first state, but when bound to the analyte exists in a second state, said change of state of the first receptor moiety causing a change in the ability of ions to pass through the ion channel, the first receptor moiety being selected from the group consisting of antigens, peptides, antibodies (e.g.Type: GrantFiled: May 23, 1995Date of Patent: December 2, 1997Assignee: Australian Membrane and Biotechnology Research InstituteInventors: Bruce Andrew Cornell, Vijoleta Lucija Bronislava Braach-Maksvytis
-
Patent number: 5688652Abstract: Methods of determining collagen degradation in vivo, by quantitating the concentration of a peptide in a body fluid, the peptide having the following structure: ##STR1## is hydroxylysyl pyridinoline or lysyl pyridinoline, and J is pyroglutamic acid or glutamine and (Leu) are optional leucines, are disclosed.Type: GrantFiled: November 22, 1995Date of Patent: November 18, 1997Assignee: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 5681707Abstract: A method of immunologically assaying intact human osteocalcin in a human assay sample is provided by using an antibody having an epitope in a region of an amino acid sequence 1 to 20 on the N-terminal side of human osteocalcinand an antibody having an epitope in a region of an amino acid sequence 36 to 49 on the C-terminal side of human osteocalcin. Furthermore, a method of immunologically assaying the total amount of human intact osteocalcin in a human assay sample is provided. A reagent and a kit therefor are also described, as well as a monclonal antibody and a polyclonal antibody used for the assay a process for producing these antibodies; and a process for use of these antibodies.Type: GrantFiled: June 5, 1995Date of Patent: October 28, 1997Assignee: Teijin LimitedInventors: Kenji Hosoda, Hitomi Honda, Takaharu Kubota, Yasuhiko Masuho
-
Patent number: 5679537Abstract: The present invention relates to a novel immunoassay for measurement of rheumatoid factors (RFs) avidity for correlation with rheumatoid arthritis disease activity and for the presence of the different glycoforms of IgG.Type: GrantFiled: October 26, 1994Date of Patent: October 21, 1997Assignee: McGill UniversityInventor: Marianna M. Newkirk
-
Patent number: 5660978Abstract: A method for stabilizing analytes with antibodies and antibody fragments comprises dissolving the analyte in a liquid to form a solution, adding analyte-specific antibodies, fragments of such antibodies, or both to the solution, heating the solution, and then cooling and filtering the solution. The filtered solution may be diluted in a suitable matrix.Type: GrantFiled: June 7, 1995Date of Patent: August 26, 1997Assignee: Ivan E. ModrovichInventors: Shing Fai Kwan, Ivan E. Modrovich, Rebecca Jolene Hunt
-
Patent number: 5656447Abstract: Polyclonal antibodies which are specific against quinolinic acid are provided. The antibodies are used for immunohistological detection of quinolinic acid.Type: GrantFiled: July 30, 1993Date of Patent: August 12, 1997Assignee: Georgetown UniversityInventors: M. A. Aryan Namboodiri, John R. Moffett
-
Patent number: 5650324Abstract: Monoclonal antibodies have been prepared which are of the IgG isotype and are highly specific for horseradish peroxidase. One group of antibodies inhibits at least about 95% of the normal activity of horseradish peroxidase when bound to the enzyme. A second group of antibodies inhibits less than about 20% of the enzymatic activity when bound to the enzyme, but prevents the binding of the antibodies from the first group. The antibodies in either group can be conjugated to specific binding ligands such as drugs or hormones.Type: GrantFiled: May 31, 1994Date of Patent: July 22, 1997Assignee: Johnson & Johnson Clinical Diagnostics, Inc.Inventors: Kevin Matthew Gorman, John Linforth Daiss
-
Patent number: 5643550Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the colorectal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.Type: GrantFiled: September 27, 1994Date of Patent: July 1, 1997Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Sydney Welt, Chaitanya R. Divgi, Samual Yeh, Lloyd J. Old, Herbert F. Oettgen, Francisco X. Real, Junichi Sakamoto
-
Patent number: 5627078Abstract: The present invention concerns a multivalent dextran reagent for use in a precipitation test for the determination of a specifically bindable substance comprising dextran to which several molecules of a receptor R.sub.1 which is capable of specific binding to the substance to be determined or of the specifically bindable substance or of an analogue of this substance are bound or can be bound.Type: GrantFiled: June 1, 1994Date of Patent: May 6, 1997Assignee: Boehringer Mannheim GmbHInventors: Johann Karl, Josef Maier
-
Patent number: 5620861Abstract: A method of assaying bone collagen degradation activity in a human subject. In the method, a human urine sample is reacted with an antibody which (i) is capable of reacting immunospecifically with pyridinium crosslinks selected from the group consisting of native free pyridinoline and native free deoxypyridinoline, and (ii) has a ratio of reactivity toward the selected pyridinium crosslinks and urinary pyridinium peptides larger than 1,000 daltons in molecular weight, of greater than about 5:1. An immunocomplex forms between the antibody reagent and the selected pyridinium crosslinks which are present in the sample, and the amount of immunocomplex is measured. Also disclosed are antibody reagents and kits which can be used in the method.Type: GrantFiled: June 7, 1995Date of Patent: April 15, 1997Assignee: Metra Biosystems, Inc.Inventors: Mary J. Cerelli, Hsin-Shan J. Ju, Robert F. Zuk
-
Patent number: 5604091Abstract: This invention relates to improved methods and novel compositions for enzyme complementation assays for qualitative and quantitative determination of a suspected analyte in a sample. The use of enzyme-acceptor and enzyme-donor polypeptides prepared by recombinant DNA techniques, DNA synthesis or chemical polypeptide synthesis techniques which are capable of interacting to form an active enzyme complex having catalytic activity characteristic of .beta.-galactosidase is described. Both homogeneous and heterogeneous assays utilizing these polypeptides are described.Type: GrantFiled: June 30, 1994Date of Patent: February 18, 1997Assignee: Microgenics CorporationInventor: Daniel R. Henderson
-
Patent number: 5587458Abstract: The present invention relates to novel antibodies, in particular monoclonal and single chain antibodies derived therefrom which specifically bind to erbB-2, as well as diagnostic and therapeutic uses thereof. The present invention also relates to a combination of at least two erbB-2 specific antibodies which are capable of preventing and treating human malignancies wherein the malignant cells overexpress gp185.sup.erbB-2. The monoclonal antibodies of the combination preferably recognize different epitopes of the gp185 expression product of erbB-2, therefore, the antibodies do not cross react with each other. Preferably, the combination will provide for synergistic decrease in the expression of the erbB-2 gene product.Type: GrantFiled: May 14, 1993Date of Patent: December 24, 1996Assignee: Aronex Pharmaceuticals, Inc.Inventors: C. Richter King, Philip G. Kasprzyk, Robert E. Bird
-
Patent number: 5583004Abstract: Human red blood cells with antigenic determinants recognized by unexpected alloantibodies are mixed with serum from the potential recipient. Following incubation, multivalent monoclonal IgM antibodies specific to the antigenic determinant present on the test red blood cells are added. If the recipient's serum is negative for an unexpected antibody which would bind to the antigens present on the test red blood cells, then the multivalent antibody will agglutinate the red cells. Conversely, if an unexpected antibody specific to those determinants is present in the recipient's serum, hemagglutination will be inhibited.Type: GrantFiled: December 23, 1994Date of Patent: December 10, 1996Inventor: Mathew R. Pincus
-
Patent number: 5571680Abstract: Homogeneous immunoassays and enzyme-substrate assays which use capillary electrophoresis and fluoescent detection systems are described. The method is useful for detecting and/or quantitating the concentration of analytes in a sample.Type: GrantFiled: January 21, 1994Date of Patent: November 5, 1996Assignee: Beckman Instruments, Inc.Inventor: Fu-Tai A. Chen
-
Patent number: 5552293Abstract: A monoclonal antibody that reacts with the CA-242 antigen is provided. The antibody can be obtained by culturing the hybridoma cell line C242:II with the ECACC identification number 90012601, or an artificial or spontaneous mutant thereof. Cell lines producing the antibody are also provided. The antibody is useful for therapeutic and diagnostic purposes.Type: GrantFiled: May 8, 1995Date of Patent: September 3, 1996Assignee: Pharmacia AktiebolagInventors: Leif G. Lindholm, Jan Holmgren, Peter Lind
-
Patent number: 5547846Abstract: The invention describes two immunogenic regions of the E7 protein of human papillomavirus type 16 (HPV 16), one immunoreactive region being located downstream from nucleotide 595 and the other being located downstream from nucleotide 667 of the HPV 16 genome.Type: GrantFiled: August 16, 1994Date of Patent: August 20, 1996Assignee: Behringwerke AktiengesellschaftInventors: Dusan Bartsch, Lutz Gissmann, Martin Muller
-
Patent number: 5545530Abstract: The amount of an analyte in a sample derived from a living sample is measured by reacting the analyte with an excess of a substance having affinity for the analyte, followed by separation of complex by high pressure liquid chromatography and measurement using a linear calibration curve representing the peak area values associated with known concentrations of analyte.Type: GrantFiled: May 17, 1995Date of Patent: August 13, 1996Assignee: Wako Pure Chemical Industries, Ltd.Inventors: Shinji Satomura, Kenji Nakamura, Tokuji Ikenaka, Kaoru Omichi
-
Patent number: 5541059Abstract: Immunoassay devices and methods that employ non-antibody control substances are disclosed. A non-antibody substance, such as Protein A, that specifically binds to the Fc portion of IgG is used to determine whether patient sample is properly added to the device during the assay procedure.Type: GrantFiled: December 29, 1993Date of Patent: July 30, 1996Inventor: Albert E. Chu
-
Patent number: 5534405Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, polypeptides related to HBxAg, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.Type: GrantFiled: November 18, 1994Date of Patent: July 9, 1996Assignee: The Scripps Research InstituteInventors: Ann M. Moriarty, Hannah Alexander, Richard A. Lerner
-
Patent number: 5532171Abstract: There is disclosed a novel phenothiazine derivative of the general formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and are a C.sub.1-6 alkyl group and at least one of them has as a substituent a group which can react with amino group, thiol group or carboxyl group, and X.sup.- is a counter ion of the phenazathionium. Their production and the intermediates used in the production are also disclosed. The compound (I) is a derivative of methylene blue and is applicable to photodynamic therapy of cancer or immunoassays utilizing chemiluminescence.Type: GrantFiled: May 23, 1994Date of Patent: July 2, 1996Assignee: Takeda Chemical Industries, Ltd.Inventor: Marvin A. Motsenbocker
-
Patent number: 5514559Abstract: Novel conjugate of the general formulaA--L.sub.1 --L.sub.2 --Bwherein A and B are the substances to be coupled selected from the groups of haptens, proteins, polysaccharides, soluble polystyrenes, or peptides, L.sub.1 and L.sub.2 are trivalent linkers and L.sub.1 and L.sub.2 are bound via two thioether. They can be used in immunological assays and exhibit an improved storage stability.Type: GrantFiled: March 29, 1994Date of Patent: May 7, 1996Assignee: Boehringer Mannheim GmbHInventors: Christine Markert-Hahn, Beatus Ofenloch-Haehnle, Eva Hoess, Erasmus Huber
-
Patent number: 5506111Abstract: A method of immunologically assaying intact human osteocalcin in a human assay sample is provided by using an antibody having an epitope in a region of an amino acid sequence 1 to 20 on the N-terminal side of human osteocalcin and an antibody having an epitope in a region of an amino acid sequence 36 to 49 on the C-terminal side of human osteocalcin. A reagent and a kit therefor are provided. Furthermore, a method of immunologically assaying the total amount of human intact osteocalcin in a human assay sample, and a reagent and a kit therefor are also provided. A monoclonal antibody and a polyclonal antibody are used for the assay. A process for producing these antibodies, and utilization of these antibodies is described.Type: GrantFiled: October 3, 1994Date of Patent: April 9, 1996Assignee: Teijin LimitedInventors: Kenji Hosoda, Hitomi Honda, Takaharu Kubota, Yasuhiko Masuho
-
Patent number: 5492814Abstract: A liquid that includes monocrystalline superparamagnetic particles and a method for preparing this liquid. Also featured are a method of decreasing the NMR relaxation times of water protons in contact with biological tissue using this liquid and an in vitro method for obtaining information from biological tissue or components thereof using this liquid.Type: GrantFiled: November 3, 1992Date of Patent: February 20, 1996Assignee: The General Hospital CorporationInventor: Ralph Weissleder
-
Patent number: 5486456Abstract: A method for detecting the presence of cancer employs monoclonal antibody OXA or OXB, antibodies which bind to the antigen bound by monoclonal antibody OXA or OXB, or fragments of the foregoing which bind to the antigen bound by monoclonal antibody OXA or OXB. The method comprises contacting a sample of a biological fluid from a subject with the antibody under conditions permitting the antibody to form a reaction product, and then detecting the presence or absence of the reaction product. The method is particularly useful for monitoring the progression of treatment in a patient previously diagnosed as having ovarian or colon cancer. The method is also useful for detecting and monitoring endometrial cancer, and for detecting colon cancer.Type: GrantFiled: March 23, 1994Date of Patent: January 23, 1996Assignee: Duke UniversityInventors: Feng J. Xu, Yin H. Yu, Robert C. Bast, Jr.
-
Patent number: 5480779Abstract: A process for determining the concentration of cyclosporine in a sample, which comprises adding to the sample a predetermined amount of an isomerase which isomerizes N-terminal peptide to proline, then measuring the enzyme-catalyzed inhibition of the isomerization of a proline-containing substrate, and determining the concentration or cyclosporine from a calibration curve.Type: GrantFiled: January 12, 1993Date of Patent: January 2, 1996Assignee: Arzneimittelwerk Dresden GmbHInventors: Gunter Fischer, Namen G. Kullertz
-
Patent number: 5460947Abstract: Two hybridomas that produce receptors containing antibody combining sites that immunoreact with apolipoprotein B-100 are disclosed as are uses for the receptors, compositions and diagnostic systems that include the receptors.Type: GrantFiled: March 30, 1994Date of Patent: October 24, 1995Assignee: The Scripps Research InstituteInventors: Steven Young, Joseph L. Witztum, Linda K. Curtiss
-
Patent number: 5445940Abstract: Provided are monoclonal antibodies, fragments, and derivatives thereof reactive with an epitope of the T cell receptor alpha chain variable region, V.alpha.12.1, on human T lymphocytes. The monoclonal antibodies are reactive with approximately 2% of CD4.sup.+ T lymphocytes and with approximately 5% of CD8.sup.+ T lymphocytes in peripheral blood cells in normal individuals and define a subset of individuals afflicted with an autoimmune disease, especially rheumatoid arthritis, that exhibit increased expression of the V.alpha.12.1 gene on CD8.sup.+ peripheral blood T lymphocytes when compared to normal individuals. Also provided are methods for diagnosing, treating, and monitoring the progression of rheumatoid arthritis in a subject using V.alpha.12.1-specific reagents, including antibodies and nucleic acid probes. Higher levels of assurance in the diagnosis of RA can be made by establishing that the expansion of V.alpha.12.1 gene usage is clonal or oligoclonal and that the V.alpha.12.Type: GrantFiled: August 26, 1992Date of Patent: August 29, 1995Assignees: Brigham & Women's Hospital, Dana-Farber Cancer InstituteInventors: Michael B. Brenner, Harout Der Simonian
-
Patent number: 5443955Abstract: The present invention provides a membrane the conductivity of which is dependent on the presence or absence of an analyte. The membrane comprises a closely packed array of self-assembling amphiphilic molecules and two ionophore components. A receptor molecule reactive with the analyte is provided on one of the ionophore components. The binding of the analyte to the receptor molecule causes a change in the relationship between the ionophore components such that the flow of ion across the membrane is prevented or allowed. The ionophore components are preferably selected from the group consisting of amphotericin B, gramicidin A monomers and combinations thereof, with gramicidin A monomers being particularly preferred. The present invention also provides a membrane including receptors directed against the Fc region of antibodies. These receptors are preferably derived from polyclonal antibodies.Type: GrantFiled: July 3, 1991Date of Patent: August 22, 1995Assignee: Australian Membrane and Biotechnology Research InstituteInventors: Bruce A. Cornell, Vijoleta L. B. Braach-Maksvytis, Ronald J. Pace, Lionel G. King, Burkhard Raguse, Claire R. Baxter, Ruth M. Hall, Carol A. Morris, Peter D. J. Osman
-
Patent number: 5436132Abstract: A method of determining tenascin in a cerebrospinal fluid sample by immunoassay, etc. is disclosed. The tenascin level in the cerebrospinal fluid serves as a glioma marker and thus the selective diagnosis of glioma is possible.Type: GrantFiled: October 22, 1993Date of Patent: July 25, 1995Assignee: Amano Pharmaceutical Co., Ltd.Inventors: Shigeki Kimura, Kinya Washizu, Jun Yoshida
-
Patent number: 5429927Abstract: The present invention provides a method of cleaving an antigen/anti-antigen or hapten/anti-hapten linkage joining two particles comprising reacting said linkage with a secondary antibody, or fragment thereof, binding to said anti-antigen or anti-hapten, and a kit for performing such a method. The method of the invention has particular utility in the separation of cells.Type: GrantFiled: November 10, 1992Date of Patent: July 4, 1995Assignee: Dynal ASInventors: John Afseth, Steiner Funderud, Laurent Caignault, Mohamad Mortada
-
Patent number: 5424192Abstract: This invention is directed to the identification, isolation and use of nonprostate derived markers, such as markers derived from the seminal vesicles, and antibodies which recognize these markers in the diagnosis of invasive proatic neoplasia, to diagnostic aids for screening biological samples for evidence of invasive prostatic neoplasia, and to methods for the use of these diagnostic aids.Type: GrantFiled: March 29, 1993Date of Patent: June 13, 1995Assignee: Baylor College of MedicineInventors: Timothy C. Thompson, Thomas P. Dooley
-
Patent number: 5422282Abstract: This invention provides a purified cochlear antigen reactive with an autoantibody associated with autoimmune sensorineuronal hearing loss. The purified antigen is defined as having a molecular weight of about 68,000 daltons as determined by SDS-PAGE analysis under reducing conditions. This invention also provides a method for detecting autoimmune sensorineural hearing loss in a patient. Finally, a kit containing reagents to assay for an antibody associated with autoimmune sensorineural hearing loss in a patient sample is disclosed and claimed by this invention.Type: GrantFiled: September 1, 1993Date of Patent: June 6, 1995Assignee: The Regents of the University of CaliforniaInventor: Jeffrey P. Harris